Combination therapy reduces relapse risk in children with eye inflammation from arthritis

A meta-analysis of randomized controlled trials examined children with juvenile idiopathic arthritis-associated uveitis. The review combined data from 177 patients to compare adalimumab plus methotrexate against other strategies. Researchers found that the combination therapy substantially reduced the risk of treatment failure or disease relapse. This approach also helped control eye inflammation early on and allowed for a reduction in corticosteroid use. Visual acuity remained preserved throughout the study period. Safety data showed that adverse events were comparable between groups, with few serious events and no emergent safety signals. The study suggests that using adalimumab with methotrexate is a preferred strategy for both starting and continuing treatment. Readers should note that this is a meta-analysis of existing trials, which provides a broad view but relies on the quality of the original studies. While the results are promising, the total number of patients was relatively small. This evidence supports a specific treatment choice but does not replace individual medical advice.